GlobeNewswire Inc | Feb 26, 2021 07:05AM EST

February 26, 2021

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

-- Cowen 41st Annual Health Care Conference, March 1 - 4, 2021Members of uniQures management team including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research & development, will participate in virtual one-on-one investor meetings throughout the day on Monday, March 1.David Cooper, M.D., vice president of clinical research CNS, will participate on a panel discussion entitled Developing and Commercializing Neurological Therapies on Thursday, March 4 at 1:30 p.m. ET. Registered conference attendees will have access to the live panel webcast. -- H.C. Wainwright Global Life Science Conference, March 9 - 10, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, March 9.A pre-recorded fireside chat with Matt Kapusta can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website on Tuesday, March 9 starting at 7:00 a.m. ET. -- 2nd Annual Gene Therapy for Blood Disorders, March 9 - 11, 2021Nick Li, Ph.D., M.B.A., senior director, global/US market access lead, will present at a workshop entitled Developing a Gene Therapy Payment Model & Pricing Strategy for Hemophilia when Alternative Treatments are Available on Thursday, March 11. -- Gene Therapy Patient Engagement, March 23 - 25, 2021Daniel Leonard, senior director of global patient advocacy, will participate in a panel discussion entitled What Does Committing to a Gene Therapy Clinical Trial Mean? starting at 10:00 a.m. ET on Thursday, March 25.Edgar Vega, senior manager of patient advocacy, will present at a workshop entitled Developing and Distributing Educational Materials on Gene Therapy in a Digital World starting at 1:30 p.m. ET on Thursday March 25 and will then participate in a panel discussion entitled What Role and Responsibility do Gene Therapy Companies Have as a Source of Relevant Information for their Communities starting at 2:30 p.m. ET. -- Stifel CNS Day, March 31 April 1, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, March 31.A fireside chat with Matt Kapusta will take place on Wednesday, March 31 from 11:00 to 11:25 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

uniQure Contacts:

FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com